Healthcare Jul 07, 2021 01:19 PM (GMT+8) · EqualOcean
June 30, 2021 - this is the latest time for innovative drugs to go on the market that can be shortlisted for this year's new round of dynamic adjustment of medical insurance catalog in the draft of "work plan for the adjustment of national medical insurance drug catalog in 2021" released by the State Medical Insurance Bureau. This means that about 40 innovative drugs or new indications approved for marketing from August 2020 to June 30, 2021 have the opportunity to be included in this year's health care negotiations. For the pharmaceutical companies holding these heavy new products, they have never adapted and responded passively. By this year, they have already had innovative strategies and ideas. Among them, the first "trump card" is to put the best innovative drugs into the Chinese market at the first time, and at the same time, deploy in advance and actively participate in China's medical insurance negotiations. Individual enterprises even cut prices in advance before the medical insurance negotiations, in order to get the first chance in the new round of medical insurance negotiations. As a new drug in the field of AML, venacla tablets (trade name: weikelai), which was approved to go on the market in December 2020, the price of a single box of 100mg "14 tablets has quietly dropped from 5950 yuan to 4860 yuan, a price reduction of 18.3%. It is reported that the drug is an oral B-cell lymphoma factor-2 (Bcl-2) inhibitor developed by aberway for the treatment of acute myeloid leukemia (AML). Venaclar tablet is the only approved Bcl-2 inhibitor in China. According to the analysis of industry insiders, from the previous rounds of medical insurance negotiations, innovative drugs approved for less than a year on the market may be successfully included in the medical insurance catalog if pharmaceutical companies take the initiative to reduce prices.

This text is a result of machine translation.